SCHEMBL30487541

SCHEMBL30487541

CCOC(=O)C[C@H](NC(=O)C1CC2(C1)CN(CCc1ccc3cccnc3n1)C2)c1ccc(OC)nc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC3 O15379 6/20 0.36
HDAC1 Q13547 6/20 0.36
HDAC2 Q92769 4/20 0.36
HDAC8 Q9BY41 4/20 0.36
HDAC6 Q9UBN7 2/20 0.36
ITGB1 P05556 3/20 0.35
ITGA4 P13612 1/20 0.35
LMNA P02545 1/20 0.33
ITGB3 P05106 4/20 0.33
ITGAV P06756 4/20 0.33
ALDH1A1 P00352 3/20 0.33
CHRNA7 P36544 2/20 0.33
KCNH2 Q12809 1/20 0.33
ITGA5 P08648 2/20 0.32
CYP2C9 P11712 1/20 0.32
CNR2 P34972 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
ITGA2B P08514 1/20 0.32
ITGB6 P18564 1/20 0.32
ITGB8 P26012 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20142707 0.92 ITGB1 (0.42) HDAC3HDAC1HDAC2HDAC8HDAC6
SCHEMBL20158254 0.89 OPRM1 (0.39) ITGB1ITGA4LMNAITGB3ITGAV
SCHEMBL30487513 0.85 ITGB3 (0.51) ITGB1ITGB3ITGAVITGA5ITGA2B
SCHEMBL23747189 0.85 ITGB3 (0.51) ITGB1ITGB3ITGAVITGA5ITGA2B
SCHEMBL30487508 0.84 ITGB1 (0.39) HDAC3HDAC1HDAC2HDAC8HDAC6
SCHEMBL26462396 0.81 ITGB1 (0.37) HDAC3HDAC1HDAC2HDAC8HDAC6
SCHEMBL28743991 0.81 ITGB1 (0.37) HDAC3HDAC1HDAC2HDAC8HDAC6
SCHEMBL21317510 0.81 ITGB1 (0.39) ITGB1ITGA4LMNAITGB3ITGAV
SCHEMBL20141568 0.80 ITGB1 (0.43) HDAC3HDAC1HDAC2HDAC8HDAC6
SCHEMBL30487546 0.78 SUCNR1 (0.40) HDAC3HDAC1HDAC2HDAC8HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11639353-B2 Cyclobutanes- and azetidine-containing mono and spirocyclic compounds as αV integrin inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2023-05-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11639353-B2 Cyclobutanes- and azetidine-containing mono and spirocyclic compounds as αV integrin inhibitors ITGB1, ITGB2, ITGA1 HDAC3 944/4885HDAC1 420/4885HDAC2 1019/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.